Thromb Haemost 1983; 50(02): 591-594
DOI: 10.1055/s-0038-1665263
Original Article
Schattauer GmbH Stuttgart

Measurement of Crosslinked Fibrin Degradation Products – An Immunoassay Using Monoclonal Antibodies

M J Elms
1   The Department of Pathology, Royal Brisbane Hospital, Brisbane, Queensland, Australia
,
I H Bunce
1   The Department of Pathology, Royal Brisbane Hospital, Brisbane, Queensland, Australia
,
P G Bundesen
2   The Centre for Applied Immunology, School of Health Science, Queensland Institute of Technology, Brisbane, Australia
,
D B Rylatt
2   The Centre for Applied Immunology, School of Health Science, Queensland Institute of Technology, Brisbane, Australia
,
A J Webber
2   The Centre for Applied Immunology, School of Health Science, Queensland Institute of Technology, Brisbane, Australia
,
P P Masci
3   The University of Queensland, Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia
,
A N Whitaker
3   The University of Queensland, Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia
› Author Affiliations
Further Information

Publication History

Received 24 May 1983

Accepted 24 June 1983

Publication Date:
18 July 2018 (online)

Zoom Image

Summary

We have prepared a monoclonal antibody which recognises an antigenic determinant on D dimer, a specific fragment resulting from the degradation of crosslinked fibrin. This antibody has been used in the development of an enzyme-linked immunoassay for D dimer and related degradation products containing crosslinked gamma-gamma chains, to provide a simple assay of circulating crosslinked fibrin degradation products suitable for clinical use. Since these crosslinked fibrin degradation products are characteristic of fibrinolysis, as distinct from fibrinogenolysis, their measurement should aid in the diagnosis, evaluation and monitoring of thrombotic and thrombolytic states. In preliminary studies, low concentrations of crosslinked fibrin derivatives were detected in normal sera. High levels were found in 30/30 patients with disseminated intravascular coagulation .and in the majority of patients having deep venous thrombosis or pulmonary embolism.